Tenax Therapeutics, Inc. (TENX): Price and Financial Metrics
GET POWR RATINGS... FREE!
TENX Stock Price Chart Interactive Chart >
TENX Price/Volume Stats
|Current price||$0.32||52-week high||$2.06|
|Prev. close||$0.30||52-week low||$0.23|
|Day high||$0.33||Avg. volume||142,034|
|50-day MA||$0.59||Dividend yield||N/A|
|200-day MA||$0.94||Market Cap||8.02M|
Tenax Therapeutics, Inc. (TENX) Company Bio
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. The company was founded in 1967 and is based in Morrisville, North Carolina.
Most Popular Stories View All
TENX Latest News Stream
|Loading, please wait...|
TENX Latest Social Stream
View Full TENX Social Stream
Latest TENX News From Around the Web
Below are the latest news stories about Tenax Therapeutics Inc that investors may wish to consider to help them evaluate TENX as an investment opportunity.
MORRISVILLE, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that Tenax Therapeutics appointed Robyn Hunter to its Board of Directors, effective January 28, 2022. Ms. Hunter is an independent director and will chair the Board’s audit and compliance committee. “We are ve
Provides Broad Coverage for Use of TNX-102 for the Treatment of Human Subjects with Any Health Condition Patent Term to 2039, Exclusive of Any Possible Extensions MORRISVILLE, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ: TENX ), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the company''s subcutaneous formulation of levosimendan, TNX-102, which is currently being developed for the treatment of pulmonary hypertension associated with left heart failure (PH-HFpEF). On January 4, 2022, Tenax Therapeutics was issued US Pat. No. 11,2...
Tenax Therapeutics (TENX) announces that the USPTO has granted a patent for the companys subcutaneous formulation of levosimendan, TNX-102, which is currently being developed for
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Clinical Program Update On January 4, 2022, Tenax Therapeutics, Inc. (NASDAQ:TENX) provided an update on TNX-102 (subcutaneous levosimendan), TNX-103 (oral levosimendan) and TNX-201 (enteric-coated imatinib in PAH). Tenax has received a Notice of Allowance from the USPTO 1 for subcutaneous administration of levosimendan
Receives a Notice of Allowance of Multiple Patent Claims for TNX-102 (subcutaneous levosimendan) Successfully Completes IV to Oral Transition Substudy for TNX-103 (oral levosimendan) Plans to Initiate Phase 3 Study of TNX-201 (oral imatinib mesylate) in Pulmonary Arterial Hypertension in 2H 2022 Forms Scientific Advisory Board with Expertise in Pulmonary Vascular Disease MORRISVILLE, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical compa
TENX Price Returns